Rutherford-based Cancer Genetics Inc., a precision medicine in oncology company, announced Wednesday it has appointed William Finger its new executive vice president, precision medicine and biopharma solutions, effective immediately.
Finger will be responsible for developing and overseeing the company’s precision medicine and biopharma, and clinical trial business unit.
Finger, who has more than 25 years of experience in the life sciences, diagnostics and lab services industry, most recently served as managing director, precision medicine and diagnostics for Kineticos. Before that, he spent more than 12 years with Laboratory Corporation of America. Early in his career he worked for Wake Health Services and Duke University Medical Center.
“We are excited to welcome Bill to Cancer Genetics as we execute on our plans to transform the business to accelerate the path to profitability by improving operational efficiency, expanding the service offerings and growing our pipeline in our Biopharma and Discovery businesses in the near term,” John A. Roberts, CEO of Cancer Genetics, said. “Bill’s long history of leading key teams at LabCorp as well as advising industry leaders will be instrumental in driving sustainable growth for our Company.”
“Cancer Genetics is committed to providing industry leading oncology diagnostic services, especially in the immuno-oncology arena, to continue improving cancer diagnosis and treatment, and empowering our biopharma partners’ development efforts,” Finger said. “I am thrilled to join the team and look forward to building and executing on our strategy to bring important new tests and services to biopharma and biotech companies that enhance the development of drugs designed to improve patient outcomes.”
